Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

Researchers have uncovered a mechanism that may trigger ALS’s earliest stages, identifying proteins that mislocalize, causing ...

This November, the nonprofit I AM ALS is launching a peer support program as part of its new campaign focused on supporting ...

He introduced ticket prices that couldn’t be beat, but asked fliers to pay extra for nearly everything, including water, ...

On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could ...

Comparing Medicare health insurance plan options – particularly between original Medicare and Medicare Advantage – can be a ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years ...

Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in ...

Neurosense Therapeutics (NASDAQ:NRSN) is developing novel treatments for neurodegenerative diseases like amyotrophic lateral ...

DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.

The University of Ghana (UG), in collaboration with Google Research Africa and the University College of London’s (UCL) ...